Drugs Losing Exclusivity in 2024
It is well known that drug companies work hard to secure robust patents on their newest drug discoveries – often resulting in lucrative earnings for many years after. But eventually patents expire and open new market opportunities for companies that can offer generic and biosimilar alternatives. Looking forward in 2024, Fierce Pharma has published a report listing the drug patents that will expire in 2024, including for blockbusters from Bristol Myers Squibb and Biogen, plus medicines with prominent histories from Novo Nordisk, Astellas and Novartis.
The following article originally appeared in Fierce Pharma.
The unrelenting churning of time means many things to many people.
For pharma executives, it’s a reminder about the need for new launches to replace revenue lost to the patent cliff.
That's because no matter how successful a drug is, it’ll eventually fall to generics or biosimilars. Take Humira, the immunology powerhouse that peaked at more than $21 billion in global sales: The drug began facing biosimilars in early 2023 and naturally suffered a sharp decline last year.
As we do each year, Fierce Pharma has assembled the list of the top drugs expected to face that fate in 2024. For inclusion in this report, we consider the drugs most likely to face new generic or biosimilar competition this calendar year, ranked by U.S. sales from last year.
The report features blockbusters from Bristol Myers Squibb and Biogen, plus medicines with storied histories from Novo Nordisk, Astellas and Novartis. Other companies facing important potential losses of exclusivity in 2024 are PTC Therapeutics, Organon, Supernus, CSL and Bausch + Lomb.
In the biopharma world, there's always uncertainty stemming from legal and regulatory developments, which can affect generic and biosimilar launch timing. We try to navigate these uncertainties by using information from company filings, conference call transcripts and outside sources to produce a reliable report.
This year, we’ve tapped lists from Corporate Pharmacy Services, Biospace and OptumRx to help identify prospects for this report.
For more, please find the original story source here.
